Regeneron Pharmaceuticals, Inc.
REGN
$828.50
-$5.54-0.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.30B | 727.20M | 844.60M | 1.46B | 1.39B |
| Total Depreciation and Amortization | 123.70M | 123.20M | 145.00M | 136.70M | 135.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.60M | 192.00M | 175.20M | -603.00M | -154.40M |
| Change in Net Operating Assets | -649.20M | 36.50M | 5.90M | 625.00M | -227.90M |
| Cash from Operations | 813.00M | 1.08B | 1.17B | 1.62B | 1.14B |
| Capital Expenditure | -240.20M | -230.60M | -248.70M | -201.40M | -219.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -300.00K | -3.00M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 147.50M | -198.30M | 469.30M | -198.50M | -875.00M |
| Cash from Investing | -92.70M | -428.90M | 220.30M | -402.90M | -1.09B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 49.20M | 163.10M | 503.50M | 40.30M | 31.50M |
| Repurchase of Common Stock | -1.18B | -867.50M | -1.19B | -667.00M | -1.07B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -96.80M | -97.80M | -92.70M | -91.20M | -92.60M |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | 0.00 |
| Cash from Financing | -1.22B | -802.20M | -780.10M | -717.90M | -1.13B |
| Foreign Exchange rate Adjustments | -300.00K | -900.00K | -300.00K | -400.00K | 400.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -504.60M | -153.10M | 610.60M | 497.50M | -1.08B |